4-氨基-5-氯-2-甲氧基苯甲酸 | 7206-70-4

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-5-氯-2-甲氧基苯甲酸
• 中文别名: 4-氨基-5-氯邻茴香酸；4-氨基-5-氯-邻茴香酸
• 英文名称: 4-amino-5-chloro-2-methoxybenzoic acid
• CAS: 7206-70-4
• 化学式: C₈H₈ClNO₃
• mdl: MFCD00038794
• 分子量: 201.609
• InChiKey: RVEATKYEARPWRE-UHFFFAOYSA-N

物化性质

• 熔点：
  206 °C (dec.) (lit.)
• 沸点：
  369.7±42.0 °C(Predicted)
• 密度：
  1.3639 (rough estimate)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）
• 稳定性/保质期：

  遵照规格使用和储存则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S28,S36,S38
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  2922509090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  密封于阴凉干燥处。

SDS

Name:	4-Amino-5-Chloro-2-Methoxybenzoic Acid 98+% Material Safety Data Sheet
Synonym:	None known
CAS:	7206-70-4

Section 1 - Chemical Product MSDS Name:4-Amino-5-Chloro-2-Methoxybenzoic Acid 98+% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
7206-70-4	4-Amino-5-Chloro-2-Methoxybenzoic Acid	>98	230-582-3

Hazard Symbols: XN
Risk Phrases: 22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 7206-70-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 205.00 - 208.00 deg C
Autoignition Temperature: 530 deg C ( 986.00 deg F)
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: > 206 deg C
Solubility in water: 90 MG/L (20C)
Specific Gravity/Density:
Molecular Formula: C8H8ClNO3
Molecular Weight: 201.61

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 7206-70-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Amino-5-Chloro-2-Methoxybenzoic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
Safety Phrases:
S 28A After contact with skin, wash immediately with
plenty of water.
S 28B After contact with skin, wash immediately with
plenty of water and soap.
S 37 Wear suitable gloves.
S 38 In case of insufficient ventilation, wear
suitable respiratory equipment.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 7206-70-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 7206-70-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 7206-70-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

西沙必利中间体。

用途简介

反应信息

• 作为反应物：
  描述：

  4-氨基-5-氯-2-甲氧基苯甲酸 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 甲氧氯普胺
  参考文献：
  名称：

  The interaction of ammonium, sulfonium, and sulfide analogs of metoclopramide with the dopamine D2 receptor

  摘要：

  A series of permanently charged ammonium and sulfonium analogues of metoclopramide as well as a permanently uncharged sulfide analogue were synthesized and evaluated for their ability to inhibit apomorphine-induced responses on mouse striatal slices. Three of the four permanently charged analogues were found to inhibit apomorphine's effects, although at higher concentrations than either metoclopramide or its dimethyl analogue. In contrast, the sulfide analogue was inactive at concentrations up to 100 muM. These findings are consistent with earlier studies of chlorpromazine and sulpiride analogues and provide further evidence that dopamine antagonists bind in their charged molecular forms to anionic sites on the D2 receptor. Further, the results of this study in conjunction with those of our earlier sulpiride study would seem to indicate that differences in the biological profiles of metoclopramide, a type 1 benzamide useful as a gastric prokinetic agent, and sulpiride, a type 2 benzamide useful for its antipsychotic effects, are not due to any appreciable differences in the binding of the basic nitrogen atom of these molecules.

  DOI：

  10.1021/jm00073a017
• 作为产物：
  描述：

  4-氨基水杨酸 在 N-氯代丁二酰亚胺 、 硫酸 、 溶剂黄146 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 4-氨基-5-氯-2-甲氧基苯甲酸
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Berberine Derivatives as IBS Modulator

  摘要：

  肠易激综合征是最常见的功能性胃肠道疾病，其特点是慢性腹痛或不适，并伴有排便习惯的改变。5-HT 受体调节剂已被开发为肠易激综合征的治疗药物，并被证明能有效治疗该疾病。在这封信中，我们设计并合成了 12 种小檗碱衍生物作为 5-HT 受体调节剂。初步生物测试表明，这些新化合物在治疗肠易激综合征方面具有良好的活性。

  DOI：

  10.2174/157018012800389386
• 作为试剂：
  描述：

  4-氨基-5-氯-2-甲氧基苯甲酸 、 (R)-quinuclidin-3-yl 6-((3S,4R)-4-amino-3-methoxypiperidin-1-yl)hexanoate 在 4-氨基-5-氯-2-甲氧基苯甲酸 作用下， 生成 Naronapride
  参考文献：
  名称：

  WO2007149929A1

  摘要：

  公开号：

文献信息

• Preparation andIn Vitro Pharmacology of 5-HT4 Receptor Ligands. Partial Agonism and Antagonism of Metoclopramide Analogous Benzoic Esters
  作者：Sigurd Elz、Andreas Keller

  DOI：10.1002/ardp.19953280705

  日期：——

  functional in vitro assays with regard to affinity for serotoninergic 5‐HT4, 5‐HT3 and muscarinic M3 receptors. The affinities for 5‐HT4 and M3 receptors were below 6.0 (pKB or pA2). On 5‐HT4 receptors in guinea‐pig ileal longitudinal muscle and rat oesophagus, the majority of compounds revealed partial 5‐HT4 receptor agonism susceptible to blockade by SDZ 205557, a reference 5‐HT4 receptor antagonist

  胃促动力苯甲酰胺甲氧氯普胺 (1) 的脂环酯类似物及其酯同源物 SDZ 205557 (2)，一种 5-HT4 受体拮抗剂，通过 4-氨基-5-氯-2-甲氧基苯甲酸酯与 N-( 2-氯乙基）取代的脂环胺。化合物13b的溴和碘类似物（2-（1-哌啶基）乙基4-氨基-5-氯-2-甲氧基苯甲酸酯）通过脱氯-13b与N-卤代琥珀酰亚胺的卤化得到。在功能性体外试验中评估了该系列对 5-羟色胺能 5-HT4、5-HT3 和毒蕈碱 M3 受体的亲和力。5-HT4 和 M3 受体的亲和力低于 6.0（pKB 或 pA2）。在豚鼠回肠纵肌和大鼠食管中的 5-HT4 受体上，大多数化合物显示出部分 5-HT4 受体激动作用，容易被 SDZ 205557 阻断，参考 5-HT4 受体拮抗剂（pKb = 7.25 - 7.73（豚鼠回肠）和 7.09 - 7.43（大鼠食道））。相对激动剂效力在 5-303% (5-HT:
• [EN] AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS<br/>[FR] DÉRIVÉS AMINOPYRIMIDINIQUES UTILISÉS COMME MODULATEURS DE LRRK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013079505A1

  公开（公告）日：2013-06-06

  Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  式(I)的化合物或其药用可接受的盐，其中A、X、R1、R2、R3和R4如本文所定义。还公开了制备这些化合物的方法，并将这些化合物用于治疗与LRRK2受体相关的疾病，如帕金森病。
• Inhibitors of caspases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US06531474B1

  公开（公告）日：2003-03-11

  The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1&bgr; converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), or interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-&ggr; production and methods for treating interleukin-1, apoptosis-, and interferon-&ggr;-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.

  本发明涉及一类新型化合物，这些化合物是半胱氨酸蛋白酶抑制剂，特别是白细胞介素-1β转化酶（“ICE”）抑制剂。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制半胱氨酸蛋白酶活性，因此，可以有利地用作对抗白细胞介素-1（“IL-1”）、凋亡、干扰素-γ诱导因子（IGIF）或干扰素-γ（“IFN-γ”）介导疾病的药剂，包括炎症性疾病、自身免疫疾病、破坏性骨疾病、增生性疾病、传染性疾病和退行性疾病。本发明还涉及通过使用本发明的化合物和组合物来抑制半胱氨酸蛋白酶活性、降低IGIF产生和IFN-γ产生以及治疗白细胞介素-1、凋亡和干扰素-γ介导疾病的方法。本发明还涉及制备本发明化合物的方法。
• Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides
  作者：Shiro Kato、Toshiya Morie、Katsuhiko Hino、Tatsuya Kon、Shunsuke Naruto、Naoyuki Yoshida、Tadahiko Karasawa、Junichi Matsumoto

  DOI：10.1021/jm00167a020

  日期：1990.5

  With the purpose of obtaining more potent and selective gastric prokinetic than metoclopramide (1), a new series of N-[(2-morpholinyl)alkyl]benzamides (17-52) were synthesized and their gastric prokinetic activity was evaluated by determining effects on the gastric emptying of phenol red semisolid meal and of resin pellets solid meal in rats and mice. The morpholinyl moiety was newly designed after

  为了获得比甲氧氯普胺（1）更有效和选择性的胃动力，合成了一系列新的N-[（2-吗啉基）烷基]苯甲酰胺（17-52），并通过测定对胃泌素的作用来评估其胃动力。大鼠和小鼠胃中酚红半固体粉和树脂颗粒固体粉的胃排空。考虑到西沙必利（2）的侧链结构后，新设计了吗啉基部分，并与甲氧氯普胺和西沙必利的4-氨基-5-氯-2-甲氧基苯甲酰基偶联时产生了所需的活性。苯甲酰基的取代基的改性显着影响了活性。特别是，
• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120277224A1

  公开（公告）日：2012-11-01

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶（PASK）在人类或动物主体中活性的方法，用于治疗疾病，如糖尿病。

表征谱图